Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05581303 · ClinicalTrials.gov registry record · Phase 3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
A Phase 3 study of Atherosclerotic Cardiovascular Disease, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 7,297
- Enrollment target
- 20
- Study locations
NCT05581303: Active Phase 3 study of Atherosclerotic Cardiovascular Disease, sponsored by Amgen.
NCT05581303 is a Phase 3 study of Atherosclerotic Cardiovascular Disease that is active but no longer recruiting, run by Amgen. The registered enrollment target is 7,297 participants, roughly in line with the 7,220-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target. The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05581303, a Phase 3 study of Atherosclerotic Cardiovascular Disease, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 7,297 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olpasiran
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- Vitality Clinical Research - Beverly Hills
- University of California San Diego - La Jolla
- VA Greater Los Angeles Healthcare System - Los Angeles
- University of California Irvine - Orange
- University of California Los Angeles - Santa Monica
- Manshadi Heart Institute - Stockton
- Med Partners, Inc dba Premiere Medical Center, Inc - Toluca Lake
Alabama
- Ascension Saint Vincents Birmingham - Birmingham
- Grandview Medical Center Affinity Cardiovascular Specialists, LLC - Birmingham
- Heart Center Research LLC - Huntsville
- Mobile Heart Specialists PC - Mobile
Arizona
- Elite Clinical Studies LLC - Phoenix
- HonorHealth Research and Innovation Institute - Scottsdale
Florida
- Excel Medical Clinical Trials - Boca Raton
- Bay Area Cardiology - Brandon
Alaska
- Alaska Cardiovascular Research Foundation - Anchorage
Colorado
- UCHealth Memorial Central - Colorado Springs
Connecticut
- Cardiology Associates of Fairfield County PC - Stamford
District of Columbia
- MedStar Clinical Research - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,297 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 3 |
What the registry record for NCT05581303 still lists
NCT05581303 is an interventional study that assigns participants to a tested intervention. Its 7,297 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 7,220-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target.
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05581303 names 20 study sites across 8 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05581303 about?
NCT05581303 is a clinical study titled "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial". The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated...
What is the current status of trial NCT05581303?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 7,297 participants. The study started on 2022-12-14. Estimated completion is 2028-03-31.
What conditions does trial NCT05581303 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT05581303?
The interventions under investigation include: Placebo (DRUG), Olpasiran (DRUG).
Who is sponsoring clinical trial NCT05581303?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05581303 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05581303's enrollment target sits among peer trials
7,297 7th of 21 higher than 15 of 21 other Atherosclerotic Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerotic Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Prevent Coronary Artery Disease Trial
RECRUITING · Phase 3
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RECRUITING · Phase 3
-
Pelacarsen Roll-over Extension Program
RECRUITING · Phase 3
-
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI